Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1023/a:1008226416896 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Docetaxel-induced lung injury.
Med J Armed Forces India
December 2024
Deputy Commandant, Command Hospital (Western Command), Chandimandir, Haryana, India.
Docetaxel is a chemotherapeutic agent commonly used against breast cancer, nonsmall cell lung cancer, gastric, prostate, head and neck cancer. Docetaxel- or taxane-induced interstitial lung disease (ILD) remains a relatively rare reported adverse event. Although rare, this complication remains an important event to identify and it carries a high mortality.
View Article and Find Full Text PDFLymphangitic Carcinomatosis Presenting as Cough: A Case of Occult Metastatic Prostate Adenocarcinoma.
Case Rep Oncol Med
November 2024
Hematology/Oncology, Riverside University Health System, Moreno Valley, California, USA.
Article Synopsis
- Lymphangitic carcinomatosis (LC) is a serious condition often seen in advanced metastatic cancers, especially affecting the lungs, and presents symptoms like coughing and difficulty breathing.
- A 70-year-old man with generally good health experienced a persistent dry cough and other symptoms, leading to a diagnosis of Stage 4 prostate cancer with rare lung involvement.
- Imaging and biopsy confirmed the diagnosis, raising concerns for LC, which prompted urgent chemotherapy, highlighting the rarity of this condition in prostate cancer and its poor prognosis.
Impact of docetaxel plus ramucirumab therapy on interstitial lung disease in recurrent advanced non-small cell lung cancer patients.
Transl Lung Cancer Res
October 2024
Department of Respiratory Medicine, Fukuoka University Hospital, Fukuoka, Japan.
Article Synopsis
- A study was conducted to investigate the safety and effectiveness of docetaxel/ramucirumab (DOC/RAM) therapy in patients with advanced non-small cell lung cancer (NSCLC) who also had interstitial lung disease (ILD).
- The study found that 25% of patients with pre-existing ILD developed DOC/RAM-induced interstitial pneumonia, while no patients without ILD experienced this condition.
- Despite the increased incidence of pneumonia in those with ILD, the treatment did not significantly impact the overall treatment outcomes like objective response rate, progression-free survival, or overall survival.
Docetaxel-Induced Pneumonitis in a Patient With Metastatic Lung Adenocarcinoma.
Cureus
August 2024
Respiratory & Critical Care Medicine, Singapore General Hospital, Singapore, SGP.
Docetaxel is a taxane anti-neoplastic agent commonly used in the treatment of solid-organ tumours. Here, we describe a case of a patient with metastatic lung adenocarcinoma who had disease progression following initial treatment with a combination of pembrolizumab, pemetrexed and carboplatin. She received three cycles of docetaxel and had a favourable oncological response but was admitted for breathlessness following the third cycle.
View Article and Find Full Text PDFDetection of Docetaxel-induced Interstitial Pneumonitis on Ga-68 PSMA PET/CT Imaging.
Indian J Nucl Med
August 2024
Department of Nuclear Medicine, Postgraduate Institute of Medical Education and Research, Chandigarh, India.
Ga-68 labeled prostate-specific membrane antigen (PSMA) positron emission tomography-computed tomography (PET/CT) is increasingly recognized as the best imaging modality for disease staging and detection of recurrent prostate cancer. Despite its name, PSMA expression has been reported in the neovasculature of several nonprostatic benign and malignant pathologies. Docetaxel, a taxane antineoplastic agent, is the mainstay of treatment in castration-resistant prostate cancer and high-volume hormone-sensitive prostate cancer.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!